Objective-Oxidized products of probucol, spiroquinone and diphenoquinone, were shown to increase cell cholesterol release and plasma high-density lipoprotein (HDL) by inhibiting degradation of ATP-binding cassette transporter A1. We investigated whether these compounds enhance reverse cholesterol transport in mice. Approach and Results-Spiroquinone and diphenoquinone increased ATP-binding cassette transporter A1 protein (2.8and 2.6-fold, respectively, P<0.01) and apolipoprotein A-I-mediated cholesterol release (1.4-and 1.4-fold, P<0.01 and P<0.05, respectively) in RAW264.7 cells. However, diphenoquinone, but not spiroquinone, enhanced cholesterol efflux to HDL (+12%, P<0.05), whereas both increased ATP-binding cassette transporter G1 protein, by 1.8-and 1.6-fold, respectively. When given orally to mice, both compounds significantly increased plasma HDL-cholesterol, by 19% and 20%, respectively (P<0.05), accompanied by an increase in hepatic and macrophage ATP-binding cassette transporter A1 but not ATP-binding cassette transporter G1. We next evaluated in vivo reverse cholesterol transport by injecting RAW264.7 cells labeled with 3 H-cholesterol intraperitoneally into mice. Both spiroquinone and diphenoquinone increased fecal excretion of the macrophage-derived 3 H-tracer, by 25% and 28% (P<0.01 and P<0.05), respectively. spiroquinone/diphenoquinone did not affect fecal excretion of HDL-derived 3 H-cholesterol, implying that macrophage-to-plasma was the most important step in spiroquinone/diphenoquinone-mediated promotion of in vivo reverse cholesterol transport. Finally, spiroquinone significantly reduced aortic atherosclerosis in apolipoprotein E null mice when compared with the vehicle. Conclusions-Spiroquinone and diphenoquinone increase functional ATP-binding cassette transporter A1 in both the macrophages and the liver, elevate plasma HDL-cholesterol, and promote overall reverse cholesterol transport in vivo. These compounds are promising as therapeutic reagents against atherosclerosis. (Arterioscler Thromb Vasc Biol. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
R everse cholesterol transport (RCT) is an important part of cholesterol homeostasis in which body cholesterol is transported back to the liver for conversion to bile acids and excretion into bile and eventually feces. 1, 2 High-density lipoprotein (HDL) plays a major role in this. RCT is thus believed to protect against atherogenesis by preventing cholesterol accumulation in vascular lesions. The first step of RCT is removal of cell cholesterol as helical apolipoproteins of HDL, such as apolipoprotein A-I (apoA-I), generation of HDL particles by removing cellular lipids, which is mediated by ATP-binding transporter A1 and acceptance of cell cholesterol by HDL particles, which is mediated by ATPbinding cassette transporter G1 (ABCG1) and perhaps scavenger receptor BI (SR-BI) as well. These reactions occur in a sequential manner with ATP-binding cassette transporter A1 (ABCA1)-mediating generation of disc-like nascent HDL particles from cellular lipids and lipid-free apoA-I, 3, 4 and such HDL particles act as efficient acceptors of effluxed cholesterol, which is mediated by ABCG1 and SR-BI, to form mature spherical HDL particles. 5 Manipulation of ABCA1 or ABCG1 modulates development of atherosclerotic lesions in vivo, with deletion accelerating development 6 and overexpression retarding development, 7 indicating their synergistic roles in antiatherogenesis.
Transcriptions of ABCA1 and ABCG1 are upregulated by the liver X receptor 8 in extrahepatic cells, sensing oxidized cholesterol as a signal of an increase in cell cholesterol. ABCA1 and ABCG1 have thus emerged as targets of novel therapeutic strategies against atherosclerosis. However, liver X receptor agonists have major drawbacks, including development of fatty liver and dyslipidemia, as they inevitably activate sterol regulatory element-binding protein-1c and thereby upregulate the genes for lipogenesis. 9 An alternative approach would be to modulate post-translational regulation of ABCA1 and ABCG1 expression. We have previously shown that oxidized products of probucol, spiroquinone and diphenoquinone, enhance apoA-I-mediated cell cholesterol release by increasing ABCA1 protein through inhibition of its calpain-mediated degradation, 10 whereas their parent compound, probucol, not only retards ABCA1 degradation but also inhibits HDL biogenesis by inhibiting ABCA1 function. 10, 11 Spiroquinone and diphenoquinone increased HDL-cholesterol (HDL-C) levels and reduced development of atherosclerosis in rabbits. 10 We have also demonstrated that ABCA1 and ABCG1 undergo proteasomal degradation, and proteasome inhibitors enhanced cholesterol efflux by increasing ABCA1 and ABCG1, translating into promotion of macrophage-to-feces RCT in vivo, 12 using a validated murine assay. 13 We therefore decided to investigate how spiroquinone and diphenoquinone exert beneficial effects with respect to promotion of RCT in vivo and in this study demonstrated that spiroquinone and diphenoquinone enhance overall RCT in mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Effects of Spiroquinone/Diphenoquinone in RAW264.7 Cells
The effects of spiroquinone/diphenoquinone on ABCA1, ABCG1, and SR-BI were assessed in RAW264.7 cells. Figure 1A and 1B shows that probucol induced an increase in ABCA1 that was consistent with the previous finding. 11 Spiroquinone and diphenoquinone significantly increased ABCA1, by 2.8-and 2.6-fold, respectively, as previously demonstrated in THP-1 and murine fibroblasts. 10 Spiroquinone and diphenoquinone induced a 1.8-and 1.6-fold increase in ABCG1 expression, respectively, whereas probucol increased it only slightly. Conversely, both spiroquinone and diphenoquinone reduced SR-BI expression, by 365 and 32%, respectively. Reflecting the increase in ABCA1, spiroquinone and diphenoquinone promoted apoA-I-mediated cell cholesterol release 1.4-fold. Probucol, as expected, completely inhibited the apoA-I-mediated cholesterol release. However, HDLmediated cell cholesterol release was significantly enhanced only by diphenoquinone, by 12%, but not by spiroquinone. No effect was seen for probucol in this regard.
Spiroquinone and Diphenoquinone Increased Plasma HDL-C in Mice
To investigate whether the in vitro findings were translated into the in vivo setting, we administered spiroquinone and diphenoquinone to mice and evaluated plasma lipid profiles. Oral administration of spiroquinone and diphenoquinone for 7 days did not affect body weight, food intake, or biochemical parameters, such as plasma aspartate aminotransferase, alanine aminotransferase, and creatine phosphokinase, when compared with the vehicle. We also performed a long-term experiment, which confirmed the above results in the short-term experiments. Spiroquinone/diphenoquinone seemed to increase plasma total cholesterol levels, though the changes did not reach statistical significance (Figure 2A and 2B). HDL-C was significantly increased by both spiroquinone and diphenoquinone (19% and 20% compared with the vehicle and 27% and 18% compared with baseline, respectively; Figure 2C and 2D), being consistent with observations in rabbits. 10 Lipoprotein analyses using fast protein liquid chromatography revealed an increase in the HDL fractions, consistent with the stimulatory effects of spiroquinone and diphenoquinone on HDL-C, and showed that these compounds did not influence the HDL size ( Figure 3A and 3B). Diphenoquinone, but not spiroquinone, increased cholesterol in the low-density lipoprotein fractions. This was minimal but reproducible. We also evaluated other lipids in fast protein liquid chromatography fractions. Spiroquinone/diphenoquinone increased CE ( Figure 3C ), FC ( Figure 3D ), and PL ( Figure 3E ), similar to total cholesterol. There were no significant changes in TG ( Figure 3F ) among the treatments.
Spiroquinone and Diphenoquinone Increased ABCA1 Protein in Livers and Peritoneal Macrophages in Mice
ABCA1 protein expression was examined in mice livers and peritoneal macrophages. Figure 4A and 4B shows that oral administration of spiroquinone and diphenoquinone for 7 days increased expression of hepatic ABCA1, by 1.4-and 1.5-fold, respectively, but caused no change in ABCG1 or SR-BI, neither in N-glycosylated (≈80 kD) nor native forms (≈50 kD). Spiroquinone and diphenoquinone also increased ABCA1 in the peritoneal macrophages, by 1.5-and 1.6-fold, respectively, but induced no change in ABCG1 or SR-BI. These results were somewhat inconsistent with the in vitro findings for ABCG1 and SR-BI as shown in Figure 1 . We previously observed that cholesterol absorption contributed to in vivo RCT using ezetimibe, an inhibitor of Niemann-Pick C1-Like 1, a cholesterol transporter in the intestine. 14 Therefore, we checked mRNA levels of the cholesterol transporters, Niemann-Pick C1-Like 1 and ABCG5/8. The results revealed that spiroquinone/diphenoquinone did not affect their expression (data not shown).
Spiroquinone and Diphenoquinone Promoted Macrophage-to-Feces RCT in Mice
To further investigate whether the in vivo effects of these compounds with respect to ABCA1 in the liver and peripheral macrophages and plasma HDL-C elevation translate into promotion of RCT, overall transport of cholesterol from macrophages to feces was assessed. Appearance of 3 H-tracer was not increased in the plasma, the liver, or the bile, by spiroquinone or diphenoquinone. However, fecal 3 H-tracer excretion was increased by spiroquinone and diphenoquinone, by 25% and 28%, respectively. Thus, both compounds promoted macrophage-to-feces RCT in vivo. To further investigate which step contributed to the enhanced RCT by spiroquinone/diphenoquinone, we performed additional experiments using 3 H-CEs-labeled HDL, whereby the initial step of RCT, namely macrophage-to-plasma, was not taken into consideration. Figure 5E demonstrates that spiroquinone/diphenoquinone did not affect fecal excretion of HDLderived cholesterol, implying that macrophage-to-plasma was the most important step in the stimulatory effects of spiroquinone/diphenoquinone on in vivo RCT. We also investigated the cholesterol efflux capacity of HDL treated with spiroquinone/ diphenoquinone to assess whether the enhanced RCT resulted from alteration of HDL particles by spiroquinone/diphenoquinone that favored an increase in efflux capacity. As shown in Figure 5F , HDL cholesterol efflux capacity was not affected by spiroquinone/diphenoquinone, suggesting that HDL biogenesis on the macrophage cell surface associated with promoted ABCA1 functionality by spiroquinone/diphenoquinone might contribute to enhanced RCT.
Spiroquinone Inhibited Atherosclerotic Plaque Development in apoE Null Mice
Finally, we investigated whether spiroquinone exerted an inhibitory effect on atherosclerotic development using apoE null mice. Figure 6 shows that 12-week treatment with spiroquinone significantly reduced atherosclerotic lesion area when compared with the vehicle.
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C primary risks and its reduction has been established as a standard approach to preventing atherosclerotic diseases. Low HDL is also a strong risk for atherosclerotic vascular diseases and has been investigated as one of the next strategic targets for interventions to prevent and treat atherosclerosis. However, attempts to increase HDL have not yet been proven to decrease the risk. In this regard, inhibition of cholesteryl ester transfer protein has been unsuccessful to date in achieving a beneficial clinical outcome. 15, 16 One might raise the argument that functional aspects of HDL should be targeted rather than merely increasing HDLcholesterol to achieve clinical benefits, specifically focusing on enhancement of RCT. A recent study showed that the ability of serum HDL to promote cholesterol release from macrophages in culture is a better negative risk predictor for coronary artery disease than HDL-C. 17 In this context, increasing cellular cholesterol release should be a primary target for enhancing overall RCT. Stimulation of ABCA1 activity to generate HDL and ABCG1 activity to enhance outflow of cell cholesterol to HDL would be a rational therapeutic strategy in this regard.
Probucol, a hypolipidemic drug, is a strong inhibitor of ABCA1 and reduces plasma HDL 18, 19 but it also inhibits calpain-mediated degradation of ABCA1 causing an increase in inactive ABCA1 in cells. 11 Interestingly, the oxidative products of probucol, spiroquinone and diphenoquinone, were shown to inhibit ABCA1 degradation without inhibiting its activity, bringing about an increase active in ABCA1, which had antiatherogenic effects in rabbit. 10 Our previous study found that attenuating proteasomal degradation increased ABCA1 and ABCG1, which promoted cholesterol release from macrophages and enhanced RCT in mice. 12 In this study, we demonstrated that spiroquinone and diphenoquinone increased ABCA1 in a mouse macrophage cell line and promoted apoA-I-mediated cell cholesterol release in vitro, whereas probucol inhibited ABCA1 activity. Although spiroquinone, diphenoquinone, and probucol all increased ABCG1 protein ( Figure 1A and 1B) , only diphenoquinone increased HDL-mediated cholesterol efflux ( Figure 1D ). The specific mechanism for these findings remains to be investigated. Similar to the case of ABCA1, we could speculate that these compounds would all inhibit degradation of ABCG1, whereas probucol and spiroquinone would suppress ABCG1 activity. As diphenoquinone is downstream of spiroquinone in the oxidative pathway of probucol, it might not be inhibitory toward ABCG1. An alternative interpretation is that attenuation of SR-BI expression by probucol, spiroquinone and diphenoquinone ( Figure 1A and 1B) would counteract an increase in ABCG1. Regulation of cholesterol homeostasis would be different between liver cells and extrahepatic cells in operating RCT. In fact, regulation of ABCA1 gene expression by the cell cholesterol level in the liver seems to be in the opposite direction to that in peripheral cells unless cholesterol is overloaded, perhaps to retain cholesterol recruited from the peripheral cells to the liver. 20, 21 Although liver ABCA1 mainly contributes to the plasma HDL concentration, [22] [23] [24] it is controversial whether liver-specific modulation of ABCA1 expression has an effect on atherogenesis, 25, 26 and the findings for macrophage-specific manipulation have also been inconclusive. 26, 27 A recent study demonstrated that hepatic ABCA1 expression did not contribute to RCT, 28 while we observed that hepatic ABCA1 knockdown resulted in attenuated RCT in mice (E. Yakushiji and M. Ayaori, unpublished data, 2013). In contrast, Yamamoto et al 29 demonstrated that pharmacological inhibition of hepatic ABCA1 activity with probucol reduced HDL-C levels but promoted RCT through diversion of HDL-derived cholesterol from efflux back into plasma from excretion into the bile. In this study, spiroquinone and diphenoquinone significantly increased both hepatic and macrophage ABCA1 expression, accounting for the increase in HDL-C levels ( Figure 2C-2F ). Overall RCT from the macrophages to the feces was accordingly enhanced ( Figure 4D ). However, no apparent change was seen in the appearance of the macrophage cholesterol in the serum, the liver, or the bile ( Figure 4A-4C ). Moreover, spiroquinone/diphenoquinone did not affect fecal excretion of Figure 5 . Spiroquinone (SQ) and diphenoquinone (DQ) promoted macrophage-to-feces reverse cholesterol transport in mice. Mice were treated with 500 mg/kg of SQ, DQ, or the vehicle by oral administration. Seven days after administration, 3 H-cholesterol-labeled RAW264.7 cells were injected intraperitoneally. A, Blood samples obtained from mice 24 and 48 hours after injection were counted for 3 H-tracer radioactivity. B and C, Tracer radioactivity in the liver (B) and in the bile (C) were determined as described in Materials and Methods section of this article. D, Tracer radioactivity in the feces. Feces collected continuously from 0 to 48 hours were prepared as described in Materials and Methods section of this article, and then analyzed for tracer radioactivity. E, 3 H-cholesteryl oleate (CEs)-labeled high-density lipoprotein (HDL) were intravenously injected into mice treated with SQ/DQ or the vehicle for 7 days. Feces were collected continuously ≤48 hours and then analyzed for tracer radioactivity. Data are expressed as percent counts to total injected tracer, mean±SD; n=6 for each group. F, Using apoB-depleted plasma obtained from the mice treated with SQ/DQ or the vehicle for 7 days, HDL cholesterol efflux capacity was assayed as described in Materials and Methods section of this article. *P<0.05, **P<0.01 vs the vehicle. HDL-derived cholesterol. Taken together, these observations suggest that contribution of hepatic ABCA1 to RCT is dependent on the status of cholesterol homeostasis in hepatocytes. In the stage that hepatic ABCA1 is upregulated by liver X receptor, increase in HDL seems to be because of regurgitation of cholesterol to plasma and, therefore, may not enhance RCT even though HDL/ABCG1-mediated cholesterol efflux is increased in the peripheral tissues.
There was no apparent change in SR-BI or ABCG1 either in the liver ( Figure 3A-3B ) or in the macrophages ( Figure 3C -3D), being inconsistent with the in vitro results in RAW26437 cells. The reason for this is unknown.
In conclusion, this study demonstrated that the probucolderived oxidative products spiroquinone and diphenoquinone increase ABCA1 expression and enhance cell cholesterol release in vitro, and increase HDL-C by increasing ABCA1 in the liver and macrophages in mice. Enhancement of overall RCT by spiroquinone/diphenoquinone in vivo might be part of one of the mechanisms of their antiatherosclerotic property. These findings provide the basis of a novel therapeutic strategy for atherosclerotic diseases.
